EGFR signaling in breast cancer: Bad to the bone

John Foley, Nicole K. Nickerson, Seungyoon Nam, Kah Tan Allen, Jennifer L. Gilmore, Kenneth P. Nephew, David J. Riese

Research output: Contribution to journalReview article

97 Scopus citations


The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor tyrosine kinases. This family includes EGFR/ErbB1/HER1, ErbB2/HER2/Neu ErbB3/HER3, and ErbB4/HER4. For many years it was believed that EGFR plays a minor role in the development and progression of breast malignancies. However, recent findings have led investigators to revisit these beliefs. Here we will review these findings and propose roles that EGFR may play in breast malignancies. In particular, we will discuss the potential roles that EGFR may play in triple-negative tumors, resistance to endocrine therapies, maintenance of stem-like tumor cells, and bone metastasis. Thus, we will propose the contexts in which EGFR may be a therapeutic target.

Original languageEnglish (US)
Pages (from-to)951-960
Number of pages10
JournalSeminars in Cell and Developmental Biology
Issue number9
StatePublished - Dec 2010


  • Bone metastasis
  • Epidermal growth factor receptor
  • Resistance to endocrine therapy
  • Stem-like tumor cells
  • Triple-negative tumors

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'EGFR signaling in breast cancer: Bad to the bone'. Together they form a unique fingerprint.

  • Cite this